HDFC Pharma and Healthcare Fund

A Sectoral/Thematic Fund scheme from HDFC Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF179KC1HO1).

NAV ₹23.4590 on 16 November 2026.

Expense ratio

Total expense ratio 1.05% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.71%, brokerage 0.05%, transaction costs 0.01%, statutory levies including GST 0.28%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year30.7%14.2%-9.8%1.671.69
3 years31.3%14.4%-14.9%1.691.59

Too little NAV history for the 5, 10-year figures.

Category rank: 1st of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 98.8% of the portfolio.

  1. Divi's Laboratories Limited — 9.44%
  2. Sun Pharmaceutical Industries Limited — 7.74%
  3. Dr. Reddy's Laboratories Limited — 6.66%
  4. Apollo Hospitals Enterprise Limited — 5.19%
  5. Alkem Laboratories Limited — 4.75%
  6. Cipla Limited — 4.06%
  7. Acutaas Chemicals Limited — 3.70%
  8. Max Healthcare Institute Limited — 3.44%
  9. Aster DM Quality Care Limited — 3.37%
  10. Lupin Limited — 3.35%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.